التفاصيل البيبلوغرافية
العنوان: |
Preservation amidst decline: wake‐promoting histaminergic system provides a novel target to mitigate sleep/wake dysfunction in Alzheimer's disease. |
المؤلفون: |
Satpati, Abhijit, Pereira, Felipe Luiz, Soloviev, Alexander V., Mladinov, Mihovil, Leite, Renata Elaine Paraizo, Suemoto, Claudia Kimie, Rodriguez, Roberta Diehl, Paes, Vitor Ribeiro, Walsh, Christine M, Spina, Salvatore, Seeley, William W., Pasqualucci, Carlos Augusto, Jacob‐Filho, Wilson, Neylan, Thomas C., Grinberg, Lea T. |
المصدر: |
Alzheimer's & Dementia: The Journal of the Alzheimer's Association; Dec2024 Supplement 1, Vol. 20, p1-5, 5p |
مستخلص: |
Background: Excessive daytime sleepiness is a common and early symptom of Alzheimer's disease (AD). The subcortical wake‐promoting neurons in the lateral hypothalamic area, tuberomammillary nucleus (TMN), and locus coeruleus synchronize to maintain wakefulness/arousal. Although significant neuronal decline occurs in wake‐promoting regions, the TMN histaminergic neurons remain relatively more intact than orexinergic and nor‐adrenergic neurons. The preserved histaminergic neurons could be a potential target for addressing sleep dysfunction when neurons in the wake‐promoting system degenerate. We aimed to map neuropathological and molecular events in poorly understood histaminergic neurons across AD progression in the human TMN to help understand pathogenic features and guide therapeutic strategies. Method: We used unbiased stereology and double‐immunohistochemistry to quantify pTau (CP13) accumulation, the number of histaminergic, and total neurons in the TMN in subjects across progressive Braak stages (n = 20). Data were analyzed using the Wilcoxon signed‐rank test. We used a customized Neuropathology nCounter® (Nanostring) panel for proteomic analysis. Wald statistical test was used to compare the groups, and the genes were considered differentially expressed when the p‐value was <0.05. Result: TMN total neuronal count remained constant across Braak groups (BG), underscoring TMN's resilience to AD compared to other wake‐promoting neurons. Histaminergic (HDC+CP13‐) neurons declined between BG 0‐2 and 5‐6 (p = 0.013). The number, proportion, and density of pTau inclusions in histaminergic and total TMN neurons increased across BG (p<0.05) (Fig. 1, Table 1). In Braak 5‐6 over 0‐2, we found 284 differentially expressed genes in TMN, of which 171 were upregulated. Gene ontology analysis demonstrated upregulation of cytokine‐cytokine receptor interaction pathways (p = 0.015). In Braak 5‐6 over 0‐2, histamine decarboxylase (HDC) expression was downregulated (lfc = ‐0.819, p = 0.37) with increased expression of histamine receptors HRH1 (lfc = 1.26, p = 0.028) and HRH2 (lfc = 1.76, p = 0.019) (Fig. 2). Conclusion: Stereological data revealed that the decline in histaminergic neurons is associated with pTau accumulation and reduced histamine synthesis rather than neuronal loss. This is corroborated by a decrease in HDC expression and an upregulation of histaminergic receptor expression (potentially compensatory) in late Braak stages. Interventions focused on pTau removal may succeed in reinstating histaminergic neuro‐transmission/‐modulation, improving cognition, and restoring sleep‐wake dysfunction in AD patients. [ABSTRACT FROM AUTHOR] |
|
Copyright of Alzheimer's & Dementia: The Journal of the Alzheimer's Association is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
قاعدة البيانات: |
Supplemental Index |